Dual BRAF-EGFR Targeting by Lantadene and Peronemin Derivatives from Peronema canescens: A Molecular Docking and ADMET-Based Computational Study Against Drug-Resistant Non-Small Cell Lung Cancer (NSCLC)

Rizki Rachmad Saputra; Reny Rosalina; Rian Ka Praja

doi:10.32734/jcnar.v8i1.26908

Authors

Rizki Rachmad Saputra Department of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Palangka Raya, Central Kalimantan, 73111, Indonesia https://orcid.org/0009-0009-1442-9573
Reny Rosalina Department of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Palangka Raya, Central Kalimantan, 73111, Indonesia
Rian Ka Praja Department of Microbiology, Faculty of Medicine, Universitas Palangka Raya, Central Kalimantan, 73111, Indonesia

DOI:

https://doi.org/10.32734/jcnar.v8i1.26908

Keywords:

Peronema canescens, Lantadene, Peronemin, Molecular Docking, BRAF, EGFR, NSCLC, ADMET

Abstract

Non-Small Cell Lung Cancer (NSCLC) accounts for roughly 85% of all diagnosed lung cancers, making it the dominant clinical subtype of the disease and a leading contributor to cancer mortality worldwide. Two receptor-linked signalling nodes, driven respectively by the epidermal growth factor receptor (EGFR) and the serine/threonine kinase BRAF, sit at the centre of NSCLC pathogenesis; their reciprocal crosstalk sustains downstream MAPK signalling, drives aggressive tumour progression, and underlies clinical resistance to single-target therapy. These observations justify a search for agents capable of engaging both nodes simultaneously. Peronemacanescens (locally known as sungkai), a Kalimantan medicinal plant long used in Dayak traditional practice, has attracted growing pharmacological interest for its anticancer properties. This study evaluated the in silico anticancer potential of ten natural compounds isolated from P. canescens leaves alongside five reference/standard compounds against three structurally characterised NSCLC-relevant targets, namely wild-type EGFR (PDB 1M17), the resistance-associated mutated EGFR (PDB 5UG8), and BRAF (PDB 6B8U), using AutoDock Vina. Absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiles were subsequently predicted using the SwissADME platform. The docking results identified Lantadene A, Lantadene B, and Peronemin A3 as the most consistently favourable ligands across all three receptors. Against mutated EGFR specifically, Lantadene B, Lantadene A, and Peronemin A3 achieved binding energies of −9.1, −8.8, and −8.6 kcal mol⁻¹, respectively, while Peronemin A3 additionally displayed the highest interaction similarity to the native ligand (82.35%) of all compounds tested. All three lead compounds also engaged BRAF favourably and exhibited acceptable ADMET and drug-likeness profiles. Collectively, these computational findings position Lantadene A, Lantadene B, and Peronemin A3 as promising dual BRAF-EGFR-directed lead candidates for NSCLC that merit further in vitro and in vivo validation.

Downloads

Download data is not yet available.

References

[1] J. Zhou, Y. Xu, J. Liu, L. Feng, J. Yu, and D. Chen, "Global burden of lung cancer in 2022 and projections to 2050: Incidence and mortality estimates from GLOBOCAN," Cancer Epidemiology, vol. 93, p. 102693, 2024/12/01/ 2024.

[2] F. Bray et al., "Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries," CA: A Cancer Journal for Clinicians, vol. 74, no. 3, pp. 229-263, 2024/05/01 2024.

[3] Q. Huang et al., "Advances in molecular pathology and therapy of non-small cell lung cancer," Signal Transduction and Targeted Therapy, vol. 10, no. 1, p. 186, 2025/06/15 2025.

[4] B. Stanzione et al., "Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Common Mutations: New Strategies," Cancers, vol. 17, no. 9, p. 1515. doi: 10.3390/cancers17091515

[5] K. Fu, F. Xie, F. Wang, and L. Fu, "Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance," Journal of Hematology & Oncology, vol. 15, no. 1, p. 173, 2022/12/08 2022.

[6] Y. Xiang et al., "Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges," Frontiers in Immunology, Review vol. Volume 15 - 2024, 2024.

[7] L. H. Al-Wahaibi, A. F. Mohammed, M. H. Abdelrahman, L. Trembleau, and B. G. M. Youssif, "Design, Synthesis, and Antiproliferative Activity of New 5-Chloro-indole-2-carboxylate and Pyrrolo[3,4-b]indol-3-one Derivatives as Potent Inhibitors of EGFRT790M/BRAFV600E Pathways," Molecules, vol. 28, no. 3, p. 1269. doi: 10.3390/molecules28031269

[8] M. Z. El-Readi et al., "Multiple Molecular Mechanisms to Overcome Multidrug Resistance in Cancer by Natural Secondary Metabolites," Frontiers in Pharmacology, Review vol. Volume 12 - 2021, 2021.

[9] A. H. Ahkam, Y. Susilawati, and S. A. Sumiwi, " Peronema canescens as a Source of Immunomodulatory Agents: A New Opportunity and Perspective," Biology, vol. 13, no. 9, p. 744. doi: 10.3390/biology13090744

[10] D. Dwisari et al., "Study of Sungkai (Peronema canescens, Jack) Leaf Extract Activity as an Immunostimulators With In vivo and In vitro Methods," Pharmacognosy Journal, vol. 13, no. 6, 2021.

[11] A. Ibrahim and S. S. , Bambang Prajogo Eko Wardojo, Potential anticancer activities of chloroform subfraction from Peronema leaf on colon cancer HT-29 cells in vitro %J Journal of Applied Pharmaceutical Science. ssue: 12, 2021, pp. 082–089.

[12] N. Anjayani, S. P. Amalia, L. Sukmarini, H. A. Tamhid, G. Primahana, and A. Triastuti, "Metabolomic and Cytotoxicity Profiles of Ethanol Extract of Peronema canescens Jack on Human Non-small Lung Cancer Cell A549," Jurnal Sains Farmasi & Klinis, vol. 12, no. 1, pp. 7-14, 07/01 2025.

[13] S. K. Suthar, J. Monga, M. Sharma, and S.-Y. Lee, "Synthesis, biological evaluation, and in silico studies of lantadene-derived pentacyclic triterpenoids as anticancer agents targeting IKK-β," Journal of Biomolecular Structure and Dynamics, vol. 43, no. 18, pp. 10548-10564, 2025/12/12 2025.

[14] Suryati, Imelda, and E. Deswita, "Cytotoxic, Docking, and Pharmacokinetic Evaluation of Ethyl Acetate Fraction of Sungkai ( Peronema canescens Jack) Leaves Against A549 Lung Cancer Cells," Iraqi Journal of Pharmaceutical Sciences, vol. 35, no. 2, pp. 188-200, 06/24 2026.

[15] F. A. Dain Md Opo et al., "Identification of novel natural drug candidates against BRAF mutated carcinoma; An integrative in-silico structure-based pharmacophore modeling and virtual screening process," Frontiers in Chemistry, Original Research vol. Volume 10 - 2022, 2022.

[16] H. Naykwadi and R. R. Alavala, "Overcoming Resistance in EGFR-Mutant Cancers: A Comprehensive Review of Inhibitor Evolution and SAR-Based Design," Drug Development Research, vol. 87, no. 1, p. e70220, 2026/02/01 2026.

[17] I. Ifora, F. Fauziah, and S. A. Mayora, "Aktivitas anti-inflamasi dan daya hambat siklooksigenase-2 ekstrak etanol daun tembelekan ( Lantana camara L.)," Jurnal Farmasi Higea, vol. 12, no. 1, pp. 32-39, 2020.

[18] R. Martha et al., "Biomolecules of interest present in the main industrial wood species used in indonesia-a review," Journal of Renewable Materials, vol. 9, no. 3, pp. 399-449, 2021.

[19] M. R. R. Rahardhian, Y. Susilawati, I. Musfiroh, R. M. Febriyanti, S. S. A. Muchtaridi, and S. Sumiwi, "In silico study of bioactive compounds from Sungkai ( Peronema canescens ) as immunomodulator," Int J App Pharm, vol. 14, no. 4, pp. 135-141, 2022.

[20] M. R. R. Rahardhian, Y. Susilawati, I. D. A. Musfiroh, R. M. Febriyanti, Muchtaridi, and S. A. Sumiwi, "IN SILICO STUDY OF BIOACTIVE COMPOUNDS FROM SUNGKAI (PERONEMA CANESCENS) AS IMMUNOMODULATOR," International Journal of Applied Pharmaceutics, vol. 14, no. 4, pp. 135-141, 11/26 2022.

[21] 勲. 北川 et al., "Indonesian Medicinal Plants. VII. Seven New Clerodane-Type Diterpenoids, Peronemins A₂, A₃, B₁, B₂, B₃, C₁, and D₁, from the Leaves of Peronema canescens (Verbenaceae)," CHEMICAL & PHARMACEUTICAL BULLETIN, vol. 42, no. 5, pp. 1050-1055, 1994.

[22] I. Kitagawa et al., "Indonesian medicinal plants. VII. Seven new clerodane-type diterpenoids, peronemins A2, A3, B1, B2, B3, C1, and D1, from the leaves of Peronema canescens (Verbenaceae)," Chemical and pharmaceutical bulletin, vol. 42, no. 5, pp. 1050-1055, 1994.

[23] J. Eberhardt, D. Santos-Martins, A. F. Tillack, and S. Forli, "AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings," Journal of Chemical Information and Modeling, vol. 61, no. 8, pp. 3891-3898, 2021.

[24] J. Senkiv et al., "Novel putative ligands of cannabinoid receptors: synthesis and effects on cell signaling and neuronal functions," The Ukrainian Biochemical Journal, vol. 95, pp. 31-43, 04/26 2023.

[25] A. Daina, O. Michielin, and V. Zoete, "SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules," Scientific Reports, vol. 7, no. 1, p. 42717, 2017/03/03 2017.

[26] K. Shi et al., "Emerging strategies to overcome resistance to third-generation EGFR inhibitors," Journal of Hematology & Oncology, vol. 15, no. 1, p. 94, 2022/07/15 2022.

[27] A. K. B. Aljohani et al., "Anticancer evaluations of iodoquinazoline substituted with allyl and/or benzyl as dual inhibitors of EGFRWT and EGFRT790M: design, synthesis, ADMET and molecular docking," RSC Advances, vol. 14, no. 12, pp. 7964-7980, 2024.

[28] K. Khaddour et al., "Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies," Cancers, vol. 13, no. 13, p. 3164. doi: 10.3390/cancers13133164

[29] A. Kondo, K. J. Fujimoto, S.-i. Koda, S. Saito, and T. Yanai, "Osimertinib’s Proton-Catalyzed, Pseudoconcerted EGFR Inhibition Guides Next-Generation Inhibitor Design," Journal of Chemical Information and Modeling, vol. 66, no. 2, pp. 1203-1213, 2026.

[30] R. S. Iyer et al., "Drug-resistant EGFR mutations promote lung cancer by stabilizing interfaces in ligand-free kinase-active EGFR oligomers," Nature Communications, vol. 15, no. 1, p. 2130, 2024/03/19 2024.

[31] A. Suriñach et al., "High-Throughput Prediction of the Impact of Genetic Variability on Drug Sensitivity and Resistance Patterns for Clinically Relevant Epidermal Growth Factor Receptor Mutations from Atomistic Simulations," Journal of Chemical Information and Modeling, vol. 63, no. 1, pp. 321-334, 2022.

[32] F. A. D. M. Opo et al., "Pharmacophore-based virtual screening approaches to identify novel molecular candidates against EGFR through comprehensive computational approaches and in-vitro studies," Frontiers in Pharmacology, Original Research vol. Volume 13 - 2022, 2022.

[33] S. M. Agarwal, P. Nandekar, and R. Saini, "Computational identification of natural product inhibitors against EGFR double mutant (T790M/L858R) by integrating ADMET, machine learning, molecular docking and a dynamics approach††Electronic supplementary information (ESI) available. See https://doi.org/10.1039/d2ra00373b," RSC Advances, vol. 12, no. 26, pp. 16779-16789, 2022/06/01/ 2022.

[34] P. Khodlan et al., "Towards identification of novel inhibitors of EGFR mutants through in-silico approach," Cancer Treatment and Research Communications, vol. 47, p. 101179, 2026/01/01/ 2026.

[35] A. K. B. Aljohani et al., "Anticancer evaluations of iodoquinazoline substituted with allyl and/or benzyl as dual inhibitors of EGFR(WT) and EGFR(T790M): design, synthesis, ADMET and molecular docking," (in eng), RSC Adv, vol. 14, no. 12, pp. 7964-7980, Mar 6 2024.

[36] G. Choi, D. Kim, and J. Oh, "AI-Based Drug Discovery of TKIs Targeting L858R/T790M/C797S-Mutant EGFR in Non-small Cell Lung Cancer," Frontiers in Pharmacology, Original Research vol. Volume 12 - 2021, 2021.

[37] F. Wittlinger et al., "Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors," Communications Chemistry, vol. 7, no. 1, p. 38, 2024/02/20 2024.

[38] J. P. Robichaux et al., "Structure-based classification predicts drug response in EGFR-mutant NSCLC," Nature, vol. 597, no. 7878, pp. 732-737, 2021/09/01 2021.

[39] K. W. Hoyt et al., "Pitfalls and Considerations in Determining the Potency and Mutant Selectivity of Covalent Epidermal Growth Factor Receptor Inhibitors: Miniperspective," Journal of Medicinal Chemistry, vol. 67, no. 1, pp. 2-16, 2023.

[40] J. Chmielecki et al., "Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer," Nature Communications, vol. 14, no. 1, p. 1070, 2023/02/27 2023.

[41] D. Callegari et al., "L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib††Electronic supplementary information (ESI) available: pKa shift for Cys797; geometries of TSs identified with QM/MM calculations; analysis of the minimum free-energy path for Cys797 alkylation; analysis of MD replicas; convergence for US simulations; replica of simulation of Cys797 alkylation; conformational FESs obtained from each MD replica. See DOI: 10.1039/c7sc04761d," Chemical Science, vol. 9, no. 10, pp. 2740-2749, 2018/03/07/ 2018.

[42] J. Lategahn et al., "Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S," (in eng), Chem Sci, vol. 10, no. 46, pp. 10789-10801, Dec 14 2019.

[43] F. Poggialini et al., "Biological Evaluation and In Vitro Characterization of ADME Profile of In-House Pyrazolo[3,4-d]pyrimidines as Dual Tyrosine Kinase Inhibitors Active against Glioblastoma Multiforme," (in eng), Pharmaceutics, vol. 15, no. 2, Jan 30 2023.

[44] M. Gamal, "Indole–1,2,4-triazole hybrids as selective ERK inhibitors: Synthesis, anticancer evaluation, and molecular modeling," Current Chemistry Letters, 07/28 2025.

[45] E. Muratspahić et al., "Design and structural validation of peptide–drug conjugate ligands of the kappa-opioid receptor," Nature Communications, vol. 14, no. 1, p. 8064, 2023/12/06 2023.

[46] P. Jia, R. Hu, G. Pei, Y. Dai, Y.-Y. Wang, and Z. Zhao, "Deep generative neural network for accurate drug response imputation," Nature Communications, vol. 12, no. 1, p. 1740, 2021/03/19 2021.

[47] M. R. V. Finlay et al., "Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated Resistance," Journal of Medicinal Chemistry, vol. 64, no. 18, pp. 13704-13718, 2021.

[48] A. Mohammad et al., "Integrating virtual screening, pharmacoinformatics profiling, and molecular dynamics: identification of promising inhibitors targeting 3CLpro of SARS-CoV-2," Frontiers in Molecular Biosciences, Original Research vol. Volume 10 - 2023, 2024.

[49] J. M. Paggi, A. Pandit, and R. O. Dror, "The Art and Science of Molecular Docking," vol. 93, no. Volume 93, 2024, pp. 389-410, 2024.

[50] T. I. Adelusi et al., "Molecular modeling in drug discovery," Informatics in Medicine Unlocked, vol. 29, p. 100880, 2022/01/01/ 2022.

[51] G. Patlewicz, N. Jeliazkova, R. J. Safford, A. P. Worth, and B. Aleksiev, "An evaluation of the implementation of the Cramer classification scheme in the Toxtree software," SAR and QSAR in Environmental Research, vol. 19, no. 5-6, pp. 495-524, 2008, doi: 10.1080/10629360802083871.